Supplementary Material for: The Multicomponent, Multitarget Therapy SUC in Cats with Chronic Kidney Disease: A Multicenter, Prospective, Observational, Nonrandomized Cohort Study

<b><i>Background:</i></b> We compared the natural multicomponent, multitarget therapy SUC (Solidago compositum ad us. vet., Ubichinon compositum and Coenzyme compositum, Heel GmbH, Baden-Baden, Germany) to the well-known angiotensin-converting enzyme inhibitor benazepril in a prospective, observational, nonrandomized, two-arm cohort study of cats with chronic kidney disease (CKD). The objective was to assess the tolerability and the effectiveness of SUC in cats with CKD. <b><i>Material and Methods</i></b>: One hundred thirty-six cats were screened for CKD, and 70 cats were eligible for the study. Thirty-three cats were assigned to the SUC treatment, and 35 cats received benazepril. All cats were diagnosed with CKD. The follow-up period was 168 days. Response was assessed as an improved or stable serum creatinine from baseline to the end of the study. Additionally, a clinical summary score, as measure of quality of life, was evaluated. <b><i>Results:</i></b> Serum creatinine remained close to baseline in both study groups with slightly improved values in the SUC group. The clinical summary score improved significantly in the SUC group on days 3, 7, 28, 56 and 112, but not on day 168. <b><i>Conclusions:</i></b> Within the limitations of the study, the results carry implications for the usefulness of SUC as an interesting new treatment option for feline CKD. The results indicate that SUC might be more effective if given at least twice weekly.

<b><i>背景：</i></b> 我们在一项针对慢性肾病（CKD）患猫的前瞻性、观察性、非随机双队列研究中，将天然多组分、多靶点复方疗法SUC（由兽医级加拿大一枝黄花复方制剂Solidago compositum ad us. vet.、泛醌复方制剂Ubichinon compositum与辅酶复方制剂Coenzyme compositum组成，由德国巴登巴登的Heel有限公司生产）与临床常用的血管紧张素转换酶抑制剂（angiotensin-converting enzyme inhibitor）贝那普利（benazepril）进行了对比。本研究旨在评估SUC用于慢性肾病患猫的耐受性与有效性。<b><i>材料与方法：</i></b> 本研究共筛查了136只疑似慢性肾病的猫咪，其中70只符合入组标准。33只猫咪被分配至SUC治疗组，35只接受贝那普利治疗，所有入组猫咪均确诊为慢性肾病。随访周期为168天。疗效以血清肌酐（serum creatinine）水平自基线至研究结束时改善或稳定作为评估标准。此外，本研究还通过临床综合评分对受试猫的生活质量进行了评估。<b><i>结果：</i></b> 两组受试猫的血清肌酐水平均维持在基线附近，其中SUC组的数值略有改善。SUC组在第3、7、28、56及112天时的临床综合评分显著提升，但在第168天时未出现显著变化。<b><i>结论：</i></b> 基于本研究的局限性，本次研究结果提示SUC可作为猫慢性肾病的新型潜在治疗方案，具有一定应用价值。研究结果表明，若每周至少给药两次，SUC的临床疗效可能更佳。